Literature DB >> 7550183

MRC quality of life studies using a daily diary card--practical lessons learned from cancer trials.

P Fayers1.   

Abstract

The UK Medical Research Council (MRC) Daily Diary Card for quality of life (QOL) assessment was first designed over ten years ago, and since then has been in continuous use in cancer clinical trials organized by the MRC Cancer Trials Office. However, clinical trials using this technique have only reached maturity since 1989 and later. Thus it is timely to review the experiences gained by use of this method of assessing QOL. Results from a series of clinical trials confirm that the Daily Diary Card appears to be a valid, reliable and sensitive instrument which is able to detect the transient changes in health and QOL which occur on a day to day basis during therapy for cancer. However, in early studies we also encountered a number of problems which were addressed during later MRC trials; we believe that many of these are of general importance to any investigation of QOL in patients, many of the issues raised remain controversial, and the practical lessons learned from applying the Diary Card will be of relevance to those planning future studies of QOL assessment.

Entities:  

Mesh:

Year:  1995        PMID: 7550183     DOI: 10.1007/bf01593887

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  37 in total

1.  Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.

Authors: 
Journal:  Respir Med       Date:  1989-01       Impact factor: 3.415

2.  Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?

Authors:  P A Ganz; R A Figlin; C M Haskell; N La Soto; J Siau
Journal:  Cancer       Date:  1989-04-01       Impact factor: 6.860

3.  Night cough counts and diary card scores in asthma.

Authors:  L N Archer; H Simpson
Journal:  Arch Dis Child       Date:  1985-05       Impact factor: 3.791

4.  Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland.

Authors:  S Karjalainen; I Palva
Journal:  BMJ       Date:  1989-10-28

5.  Quality of life consequences of chemotherapy-induced emesis.

Authors:  C M Lindley; J D Hirsch; C V O'Neill; M C Transau; C S Gilbert; J T Osterhaus
Journal:  Qual Life Res       Date:  1992-10       Impact factor: 4.147

6.  Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.

Authors: 
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

7.  A daily diary for quality of life measurement in advanced breast cancer trials.

Authors:  S C Fraser; A J Ramirez; S R Ebbs; L J Fallowfield; H J Dobbs; M A Richards; T Bates; M Baum
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

8.  Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung. Medical Research Council Lung Cancer Working Party.

Authors: 
Journal:  Br J Cancer       Date:  1979-07       Impact factor: 7.640

9.  Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life.

Authors:  S C Fraser; H J Dobbs; S R Ebbs; L J Fallowfield; T Bates; M Baum
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

10.  A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party.

Authors: 
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

View more
  8 in total

1.  Evaluating the effectiveness of using PROs in clinical practice: a role for cluster-randomised trials.

Authors:  Peter M Fayers
Journal:  Qual Life Res       Date:  2008-09-27       Impact factor: 4.147

2.  An assessment of the feasibility and utility of the MS symptom and impact diary (MSSID).

Authors:  Joanne Greenhalgh
Journal:  Qual Life Res       Date:  2005-06       Impact factor: 4.147

3.  Development, feasibility and compliance of a web-based system for very frequent QOL and symptom home self-assessment after hematopoietic stem cell transplantation.

Authors:  N Bush; G Donaldson; C Moinpour; M Haberman; D Milliken; V Markle; J Lauson
Journal:  Qual Life Res       Date:  2005-02       Impact factor: 4.147

4.  Symptom-monitoring behaviors of rural cancer patients and survivors.

Authors:  Carol J Hermansen-Kobulnicky
Journal:  Support Care Cancer       Date:  2008-12-23       Impact factor: 3.603

5.  The MS Symptom and Impact Diary (MSSID): psychometric evaluation of a new instrument to measure the day to day impact of multiple sclerosis.

Authors:  J Greenhalgh; H Ford; A F Long; K Hurst
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-04       Impact factor: 10.154

6.  Yoga Practice Predicts Improvements in Day-to-Day Pain in Women With Metastatic Breast Cancer.

Authors:  James W Carson; Kimberly M Carson; Maren Olsen; Linda Sanders; Kelly Westbrook; Francis J Keefe; Laura S Porter
Journal:  J Pain Symptom Manage       Date:  2020-10-14       Impact factor: 5.576

7.  A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.

Authors:  C Gridelli; C Gallo; M Di Maio; E Barletta; A Illiano; P Maione; S Salvagni; F V Piantedosi; G Palazzolo; O Caffo; A Ceribelli; A Falcone; P Mazzanti; L Brancaccio; M A Capuano; L Isa; S Barbera; F Perrone
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

Review 8.  Patient reported outcomes (PROs) in clinical trials: is 'in-trial' guidance lacking? a systematic review.

Authors:  Derek G Kyte; Heather Draper; Jonathan Ives; Clive Liles; Adrian Gheorghe; Melanie Calvert
Journal:  PLoS One       Date:  2013-04-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.